Veru, Inc. (VERU) PT Raised to $24 at Cantor Fitzgerald

Cantor Fitzgerald analyst Brandon Folkes raised the price target on Veru, Inc. (NASDAQ: VERU) to $24.00 (from $15.00) while maintaining an Overweight rating.

The analyst commented, "Post fiscal 1Q21 earnings, we reiterate our Overweight rating on VERU stock and are raising our 12-month price target to $24, from $15. Our new price target assumes the company is able to move forward a number of its pipeline programs, and the potential for Enobosarm to potentially be a blockbuster breast cancer drug provide upside to the current stock price, and keep us constructive on the stock with a high bar set for our expectations."

You May Also Be Interested In

• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
• argenx SE (ARGX) PT Raised to $1,353 at TD Cowen